ES2635080T3 - Vacunas contra el cáncer dirigidas a células presentadoras de antígenos - Google Patents
Vacunas contra el cáncer dirigidas a células presentadoras de antígenos Download PDFInfo
- Publication number
- ES2635080T3 ES2635080T3 ES10751210.5T ES10751210T ES2635080T3 ES 2635080 T3 ES2635080 T3 ES 2635080T3 ES 10751210 T ES10751210 T ES 10751210T ES 2635080 T3 ES2635080 T3 ES 2635080T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- antigen
- cells
- cancer
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000612 antigen-presenting cell Anatomy 0.000 title description 13
- 230000008685 targeting Effects 0.000 title description 7
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 238000009566 cancer vaccine Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 350
- 108091007433 antigens Proteins 0.000 claims abstract description 308
- 102000036639 antigens Human genes 0.000 claims abstract description 308
- 239000000427 antigen Substances 0.000 claims abstract description 304
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 116
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 116
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 10
- 101150013553 CD40 gene Proteins 0.000 claims abstract 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 192
- 150000001413 amino acids Chemical class 0.000 claims description 88
- 108090000623 proteins and genes Proteins 0.000 claims description 88
- 229960005486 vaccine Drugs 0.000 claims description 82
- 235000018102 proteins Nutrition 0.000 claims description 73
- 102000004169 proteins and genes Human genes 0.000 claims description 73
- 206010028980 Neoplasm Diseases 0.000 claims description 72
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 56
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 56
- 235000001014 amino acid Nutrition 0.000 claims description 42
- 201000001441 melanoma Diseases 0.000 claims description 42
- 239000013604 expression vector Substances 0.000 claims description 33
- 150000007523 nucleic acids Chemical class 0.000 claims description 32
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 21
- 108010060385 Cyclin B1 Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 101800001271 Surface protein Proteins 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 17
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 15
- 235000004279 alanine Nutrition 0.000 claims description 15
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 14
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 14
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 14
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 14
- 208000032839 leukemia Diseases 0.000 claims description 14
- 241000701806 Human papillomavirus Species 0.000 claims description 13
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 12
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 12
- 210000004072 lung Anatomy 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 210000003734 kidney Anatomy 0.000 claims description 8
- 238000012737 microarray-based gene expression Methods 0.000 claims description 8
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 8
- 210000002307 prostate Anatomy 0.000 claims description 8
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 claims description 7
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 7
- 206010003571 Astrocytoma Diseases 0.000 claims description 7
- 208000018084 Bone neoplasm Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 108090000259 Cyclin D Proteins 0.000 claims description 7
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 7
- 101150029707 ERBB2 gene Proteins 0.000 claims description 7
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 7
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 7
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims description 7
- 108060006580 PRAME Proteins 0.000 claims description 7
- 102000036673 PRAME Human genes 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 7
- 206010034299 Penile cancer Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 230000005867 T cell response Effects 0.000 claims description 7
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 7
- 206010057644 Testis cancer Diseases 0.000 claims description 7
- 102000003425 Tyrosinase Human genes 0.000 claims description 7
- 108060008724 Tyrosinase Proteins 0.000 claims description 7
- 108010034034 alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase Proteins 0.000 claims description 7
- 210000003445 biliary tract Anatomy 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 210000003238 esophagus Anatomy 0.000 claims description 7
- 210000000232 gallbladder Anatomy 0.000 claims description 7
- 150000002270 gangliosides Chemical class 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 208000005017 glioblastoma Diseases 0.000 claims description 7
- 201000010536 head and neck cancer Diseases 0.000 claims description 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 7
- 210000000867 larynx Anatomy 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 210000000214 mouth Anatomy 0.000 claims description 7
- 210000001989 nasopharynx Anatomy 0.000 claims description 7
- 210000000653 nervous system Anatomy 0.000 claims description 7
- 230000000926 neurological effect Effects 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 210000003800 pharynx Anatomy 0.000 claims description 7
- 210000000664 rectum Anatomy 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 201000003120 testicular cancer Diseases 0.000 claims description 7
- 210000001685 thyroid gland Anatomy 0.000 claims description 7
- 210000003932 urinary bladder Anatomy 0.000 claims description 7
- 206010046885 vaginal cancer Diseases 0.000 claims description 7
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 7
- 208000020416 vascular bone neoplasm Diseases 0.000 claims description 7
- 102000003910 Cyclin D Human genes 0.000 claims description 6
- 208000017604 Hodgkin disease Diseases 0.000 claims description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
- 210000004291 uterus Anatomy 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 102000016736 Cyclin Human genes 0.000 claims description 5
- 108050006400 Cyclin Proteins 0.000 claims description 5
- 102100034263 Mucin-2 Human genes 0.000 claims description 5
- 108010008705 Mucin-2 Proteins 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 210000000621 bronchi Anatomy 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 210000001672 ovary Anatomy 0.000 claims description 5
- 108010008707 Mucin-1 Proteins 0.000 claims description 4
- 102100034256 Mucin-1 Human genes 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000000088 lip Anatomy 0.000 claims description 3
- 201000011531 vascular cancer Diseases 0.000 claims description 3
- 108010051791 Nuclear Antigens Proteins 0.000 claims description 2
- 102000019040 Nuclear Antigens Human genes 0.000 claims description 2
- 102000008178 Cyclin B1 Human genes 0.000 claims 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 2
- 102000000763 Survivin Human genes 0.000 claims 2
- 108010002687 Survivin Proteins 0.000 claims 2
- 102000016362 Catenins Human genes 0.000 claims 1
- 108010067316 Catenins Proteins 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 162
- 210000004027 cell Anatomy 0.000 description 152
- 210000001744 T-lymphocyte Anatomy 0.000 description 116
- 239000012634 fragment Substances 0.000 description 69
- 238000009739 binding Methods 0.000 description 67
- 230000027455 binding Effects 0.000 description 66
- 241000282414 Homo sapiens Species 0.000 description 59
- 238000000034 method Methods 0.000 description 58
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 46
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 46
- 230000003612 virological effect Effects 0.000 description 43
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 42
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 42
- 230000014509 gene expression Effects 0.000 description 42
- 239000000203 mixture Substances 0.000 description 42
- 239000013598 vector Substances 0.000 description 41
- 229940024606 amino acid Drugs 0.000 description 38
- 229940023041 peptide vaccine Drugs 0.000 description 34
- 230000013595 glycosylation Effects 0.000 description 33
- 238000006206 glycosylation reaction Methods 0.000 description 33
- 108020004414 DNA Proteins 0.000 description 31
- 230000000890 antigenic effect Effects 0.000 description 31
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 30
- 230000004044 response Effects 0.000 description 29
- 238000004519 manufacturing process Methods 0.000 description 28
- 102000005962 receptors Human genes 0.000 description 28
- 108020003175 receptors Proteins 0.000 description 28
- 230000028993 immune response Effects 0.000 description 26
- -1 CD31 Proteins 0.000 description 25
- 108091033319 polynucleotide Proteins 0.000 description 24
- 102000040430 polynucleotide Human genes 0.000 description 24
- 239000002157 polynucleotide Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 22
- 230000004927 fusion Effects 0.000 description 22
- 206010022000 influenza Diseases 0.000 description 22
- 229920001184 polypeptide Polymers 0.000 description 22
- 108091026890 Coding region Proteins 0.000 description 21
- 108010058546 Cyclin D1 Proteins 0.000 description 21
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 21
- 108020004705 Codon Proteins 0.000 description 20
- 102000004127 Cytokines Human genes 0.000 description 20
- 108090000695 Cytokines Proteins 0.000 description 20
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 20
- 230000001580 bacterial effect Effects 0.000 description 19
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 18
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 17
- 239000012636 effector Substances 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 210000004899 c-terminal region Anatomy 0.000 description 16
- 210000004443 dendritic cell Anatomy 0.000 description 15
- 238000010186 staining Methods 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 229940127121 immunoconjugate Drugs 0.000 description 13
- 125000006850 spacer group Chemical group 0.000 description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
- 238000013461 design Methods 0.000 description 12
- 230000002538 fungal effect Effects 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 102000000588 Interleukin-2 Human genes 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000002163 immunogen Effects 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 208000023275 Autoimmune disease Diseases 0.000 description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 8
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 108700025647 major vault Proteins 0.000 description 8
- 210000001616 monocyte Anatomy 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 7
- 201000005807 Japanese encephalitis Diseases 0.000 description 7
- 241000710842 Japanese encephalitis virus Species 0.000 description 7
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 7
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000725643 Respiratory syncytial virus Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001900 immune effect Effects 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000004224 protection Effects 0.000 description 7
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 6
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 6
- 208000005176 Hepatitis C Diseases 0.000 description 6
- 208000007514 Herpes zoster Diseases 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 6
- 102000043129 MHC class I family Human genes 0.000 description 6
- 108091054437 MHC class I family Proteins 0.000 description 6
- 102000043131 MHC class II family Human genes 0.000 description 6
- 108091054438 MHC class II family Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 101710176384 Peptide 1 Proteins 0.000 description 6
- 206010037742 Rabies Diseases 0.000 description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
- 241000702670 Rotavirus Species 0.000 description 6
- 108091008874 T cell receptors Proteins 0.000 description 6
- 241000700647 Variola virus Species 0.000 description 6
- 230000030741 antigen processing and presentation Effects 0.000 description 6
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 6
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 6
- 108010045512 cohesins Proteins 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 208000002672 hepatitis B Diseases 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 5
- 208000009889 Herpes Simplex Diseases 0.000 description 5
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 5
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 5
- 102100034353 Integrase Human genes 0.000 description 5
- 108010028921 Lipopeptides Proteins 0.000 description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 5
- 201000005505 Measles Diseases 0.000 description 5
- 101100202428 Neopyropia yezoensis atps gene Proteins 0.000 description 5
- 241000709664 Picornaviridae Species 0.000 description 5
- 241000125945 Protoparvovirus Species 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 230000003042 antagnostic effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229940030156 cell vaccine Drugs 0.000 description 5
- 108010078428 env Gene Products Proteins 0.000 description 5
- 208000005252 hepatitis A Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 201000005404 rubella Diseases 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 229940021747 therapeutic vaccine Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 4
- 101000651036 Arabidopsis thaliana Galactolipid galactosyltransferase SFR2, chloroplastic Proteins 0.000 description 4
- 241000712891 Arenavirus Species 0.000 description 4
- 102100028667 C-type lectin domain family 4 member A Human genes 0.000 description 4
- 102100035793 CD83 antigen Human genes 0.000 description 4
- 201000006082 Chickenpox Diseases 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 101710177291 Gag polyprotein Proteins 0.000 description 4
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 4
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 4
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 102000011786 HLA-A Antigens Human genes 0.000 description 4
- 108010075704 HLA-A Antigens Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000766908 Homo sapiens C-type lectin domain family 4 member A Proteins 0.000 description 4
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 4
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 4
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 4
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 4
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 4
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 4
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 4
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 4
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 4
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 4
- 102100022338 Integrin alpha-M Human genes 0.000 description 4
- 102100025304 Integrin beta-1 Human genes 0.000 description 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 4
- 102100039564 Leukosialin Human genes 0.000 description 4
- 206010062038 Lip neoplasm Diseases 0.000 description 4
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 4
- 101710125418 Major capsid protein Proteins 0.000 description 4
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 4
- 241000150452 Orthohantavirus Species 0.000 description 4
- 241001631646 Papillomaviridae Species 0.000 description 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 4
- 208000000474 Poliomyelitis Diseases 0.000 description 4
- 241001495182 Pseudobacteroides cellulosolvens Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000702263 Reovirus sp. Species 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 4
- 206010046980 Varicella Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 108010072094 gp100(280-288) melanoma antigen peptide Proteins 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003071 parasitic effect Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 3
- 102100028672 C-type lectin domain family 4 member D Human genes 0.000 description 3
- 108010029697 CD40 Ligand Proteins 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229920000324 Cellulosome Polymers 0.000 description 3
- 108010009685 Cholinergic Receptors Proteins 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 3
- 241000197306 H1N1 subtype Species 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 3
- 101000766905 Homo sapiens C-type lectin domain family 4 member D Proteins 0.000 description 3
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 3
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 241000222722 Leishmania <genus> Species 0.000 description 3
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 3
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 3
- 108010031099 Mannose Receptor Proteins 0.000 description 3
- 241000258241 Mantis Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 241000713112 Orthobunyavirus Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000606701 Rickettsia Species 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 3
- 102000011923 Thyrotropin Human genes 0.000 description 3
- 108010061174 Thyrotropin Proteins 0.000 description 3
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 3
- 102000034337 acetylcholine receptors Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000036436 anti-hiv Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000000166 cellulosome Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- NEHKZPHIKKEMAZ-ZFVKSOIMSA-N (2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s,3s)-2-[[2-[[(2s,3s)-2-[[2-[[(2s)-2-[[(2s)-2-azaniumylpropanoyl]amino]propanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylb Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O NEHKZPHIKKEMAZ-ZFVKSOIMSA-N 0.000 description 2
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 description 2
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 2
- 108010063916 CD40 Antigens Proteins 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000228402 Histoplasma Species 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000868643 Homo sapiens G2/mitotic-specific cyclin-B1 Proteins 0.000 description 2
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 2
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 2
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 2
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 2
- 101000850762 Homo sapiens TNF receptor-associated factor 3 Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 108010010995 MART-1 Antigen Proteins 0.000 description 2
- 102000016200 MART-1 Antigen Human genes 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 101710192141 Protein Nef Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000242678 Schistosoma Species 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 2
- 102100033082 TNF receptor-associated factor 3 Human genes 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 241000223996 Toxoplasma Species 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 229920004929 Triton X-114 Polymers 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 108010025838 dectin 1 Proteins 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- AWXGSYPUMWKTBR-UHFFFAOYSA-N 4-carbazol-9-yl-n,n-bis(4-carbazol-9-ylphenyl)aniline Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1C1=CC=C(N(C=2C=CC(=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)C=2C=CC(=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)C=C1 AWXGSYPUMWKTBR-UHFFFAOYSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 229940122450 Altered peptide ligand Drugs 0.000 description 1
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 1
- 101100446590 Arabidopsis thaliana FIM5 gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 102100028681 C-type lectin domain family 4 member K Human genes 0.000 description 1
- 101710183165 C-type lectin domain family 4 member K Proteins 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100035359 Cerebellar degeneration-related protein 2-like Human genes 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 description 1
- 244000098897 Chenopodium botrys Species 0.000 description 1
- 235000005490 Chenopodium botrys Nutrition 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 240000005109 Cryptomeria japonica Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 101001095863 Enterobacteria phage T4 RNA ligase 1 Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 101150106011 FIM2 gene Proteins 0.000 description 1
- 101150048576 FIM3 gene Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 101710154643 Filamentous hemagglutinin Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 239000012743 FreeStyle Max reagent Substances 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229940033332 HIV-1 vaccine Drugs 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000737792 Homo sapiens Cerebellar degeneration-related protein 2-like Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000856513 Homo sapiens Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 1
- 101000972485 Homo sapiens Lupus La protein Proteins 0.000 description 1
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 1
- 101000837344 Homo sapiens T-cell leukemia translocation-altered gene protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102100025509 Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase Human genes 0.000 description 1
- 241001539805 Influenza A virus (A/Puerto Rico/8/1934(H1N1)) Species 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102100022742 Lupus La protein Human genes 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 101150109178 M1 gene Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 101000944608 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Chaperonin GroEL 2 Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 101100494726 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pep-4 gene Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 108010071384 Peptide T Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 101710183389 Pneumolysin Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000193448 Ruminiclostridium thermocellum Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 102100028692 T-cell leukemia translocation-altered gene protein Human genes 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 241001467018 Typhis Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 210000000973 gametocyte Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 102000047813 human CCNB1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000006713 insertion reaction Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 108010008775 thyroglobulin receptor Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15905509P | 2009-03-10 | 2009-03-10 | |
| US15906209P | 2009-03-10 | 2009-03-10 | |
| US15905909P | 2009-03-10 | 2009-03-10 | |
| US159059P | 2009-03-10 | ||
| US159055P | 2009-03-10 | ||
| US159062P | 2009-03-10 | ||
| PCT/US2010/026275 WO2010104749A2 (en) | 2009-03-10 | 2010-03-04 | Antigen presenting cell targeted cancer vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2635080T3 true ES2635080T3 (es) | 2017-10-02 |
Family
ID=43068675
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16189342T Active ES2911752T3 (es) | 2009-03-10 | 2010-03-04 | Anticuerpos contra CD40 |
| ES10751210.5T Active ES2635080T3 (es) | 2009-03-10 | 2010-03-04 | Vacunas contra el cáncer dirigidas a células presentadoras de antígenos |
| ES16159238T Active ES2807232T3 (es) | 2009-03-10 | 2010-03-05 | Anticuerpos anti-CD40 y usos de los mismos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16189342T Active ES2911752T3 (es) | 2009-03-10 | 2010-03-04 | Anticuerpos contra CD40 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16159238T Active ES2807232T3 (es) | 2009-03-10 | 2010-03-05 | Anticuerpos anti-CD40 y usos de los mismos |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US8518410B2 (zh) |
| EP (2) | EP3219732A1 (zh) |
| CN (5) | CN105837691B (zh) |
| AR (2) | AR078693A1 (zh) |
| AU (2) | AU2010222929B2 (zh) |
| BR (2) | BRPI1009194A2 (zh) |
| DK (2) | DK3138854T3 (zh) |
| ES (3) | ES2911752T3 (zh) |
| MX (2) | MX2011009439A (zh) |
| PT (1) | PT3091034T (zh) |
| TW (2) | TWI542358B (zh) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010222929B2 (en) * | 2008-07-16 | 2013-07-25 | Baylor Research Institute | Antigen presenting cell targeted anti-viral vaccines |
| CA2754743C (en) | 2009-03-10 | 2020-08-25 | Baylor Research Institute | Antigen presenting cell targeted anti-viral vaccines |
| AU2010222942B2 (en) | 2009-03-10 | 2013-01-10 | Baylor Research Institute | Anti-CD40 antibodies and uses thereof |
| FR2945538B1 (fr) * | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9518087B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| BR112013002940A2 (pt) * | 2010-08-13 | 2019-09-24 | Baylor Res Institute | adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos |
| AR085633A1 (es) * | 2011-03-08 | 2013-10-16 | Baylor Res Inst | Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos |
| DK3138581T3 (en) | 2011-03-17 | 2019-04-15 | Univ Birmingham | REDIRECTED IMMUNTERY |
| CA2857645A1 (en) * | 2011-11-30 | 2013-06-06 | Wellstat Diagnostics, Llc | Assays, antibodies, immunogens and compositions related to 5-fu |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| GB2514354A (en) | 2013-05-20 | 2014-11-26 | Ibm | Managing storage devices having a lifetime of a finite number of operations |
| CA2916694C (en) | 2013-06-28 | 2023-01-17 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
| CN103409451A (zh) * | 2013-06-28 | 2013-11-27 | 扬州维克斯生物科技有限公司 | 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法 |
| FR3008099B1 (fr) | 2013-07-05 | 2020-08-07 | Commissariat Energie Atomique | Peptides immunogenes de l'antigene tumoral cycline b1 |
| EP3094652B1 (en) * | 2014-01-13 | 2021-09-29 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
| EP3107563B1 (en) | 2014-02-21 | 2021-04-07 | Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10023841B2 (en) * | 2014-05-23 | 2018-07-17 | Baylor Research Institute | Methods and compositions for treating breast cancer with dendritic cell vaccines |
| CN105821030A (zh) * | 2015-01-04 | 2016-08-03 | 彭霞 | 表达α1，3半乳糖转移酶的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法 |
| CA2971288A1 (en) | 2015-02-02 | 2016-08-11 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
| WO2017087789A1 (en) | 2015-11-19 | 2017-05-26 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| US11186618B2 (en) * | 2016-09-21 | 2021-11-30 | The Research Foundation For Microbial Diseases Of Osaka University | Dendritic-cell-targeted peptide, fusion peptide utilizing said peptide, and vaccine utilizing said fusion peptide |
| KR102389792B1 (ko) * | 2017-04-18 | 2022-04-22 | 인스티튜트 오브 패쏘젠 바이올로지, 차이니즈 아카데미 오브 메디컬 사이언시스 | Hiv를 강력하게 저해하는 리포펩티드, 그의 유도체, 그의 약학적 조성물 및 그의 용도 |
| CN108727475B (zh) * | 2017-04-18 | 2020-08-25 | 中国医学科学院病原生物学研究所 | 强效抑制hiv的脂肽、其衍生物、其药物组合物及其用途 |
| US11253579B2 (en) | 2017-06-16 | 2022-02-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
| US20210106677A1 (en) * | 2017-11-13 | 2021-04-15 | Matsfide, Inc. | Vaccine development methodology based on an adhesion molecule |
| AU2019287765A1 (en) | 2018-06-15 | 2021-01-07 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| CN110836966A (zh) * | 2018-08-15 | 2020-02-25 | 王镕 | 用于抗原特异性t细胞含量检测的检测纳米颗粒、检测方法及试剂盒等 |
| CN109251891B (zh) * | 2018-09-21 | 2021-10-22 | 苏州大学附属第一医院 | 一种cd40联合pd-l1及细胞因子扩增pbmc的方法 |
| CN111320691B (zh) * | 2018-12-17 | 2022-04-05 | 程联胜 | 一种抗人4-1bb单克隆抗体及其应用 |
| FR3090319A1 (fr) * | 2018-12-21 | 2020-06-26 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Melanges d’epitopes t cd8+ immunogenes de la cycline b1 |
| WO2020136657A1 (en) * | 2018-12-28 | 2020-07-02 | Ramot At Tel-Aviv University Ltd. | Polymeric nanovaccines and uses thereof |
| CN109678959B (zh) * | 2019-02-22 | 2020-12-08 | 北京免疫方舟医药科技有限公司 | 抗cd40抗体及其应用 |
| CN113811547B (zh) * | 2019-03-27 | 2024-06-25 | 国家医疗保健研究所 | 具有cd40激活特性的重组蛋白 |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| CA3160584A1 (en) * | 2019-12-05 | 2021-06-10 | Georgina Jane Clark | Antigen loading |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CN111330002B (zh) * | 2020-03-09 | 2020-12-01 | 北京鼎成肽源生物技术有限公司 | 靶向冠状病毒的通用dc细胞疫苗及其制备方法和应用 |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| AU2022246895A1 (en) | 2021-03-31 | 2023-10-19 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023242155A1 (en) * | 2022-06-14 | 2023-12-21 | Janssen Vaccines & Prevention B.V. | Compositions and methods for the diagnosis of hiv infection |
| WO2024073572A2 (en) * | 2022-09-29 | 2024-04-04 | Asher Biotherapeutics, Inc. | Fusions with cd8 antigen binding molecules for treating chronic viral infection |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| CN117430665B (zh) * | 2023-10-24 | 2024-06-04 | 暨南大学附属第六医院(东莞市东部中心医院) | 甲型流感病毒t细胞抗原表位肽及其应用 |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS5938877A (ja) | 1982-08-30 | 1984-03-02 | Musashi Eng Kk | 紙葉判別方法 |
| US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599231A (en) * | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) * | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) * | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5871746A (en) * | 1990-12-18 | 1999-02-16 | Institut National De La Sainte Et De La Recherche Medicale (Inserm) | Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines |
| FR2670787B1 (fr) | 1990-12-18 | 1995-06-23 | Pasteur Institut | Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins. |
| US6419931B1 (en) * | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
| US5254342A (en) * | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| JPH07507768A (ja) * | 1992-03-12 | 1995-08-31 | アルカーメス コントロールド セラピューティクス，インコーポレイテッド | Ａｃｔｈ含有マイクロスフェアの制御放出 |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| DE4233152A1 (de) | 1992-10-02 | 1994-04-07 | Behringwerke Ag | Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung |
| US6140059A (en) | 1993-01-16 | 2000-10-31 | Schawaller; Manfred | Methods for the obtention of human immunodeficiency virsus Type 1 envelope glycoproteins in native and oligomeric form employing recombinant chimeric antigens containing collagenase recognition sites. |
| US5514670A (en) * | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| DK0721469T3 (da) * | 1993-09-02 | 2000-05-01 | Dartmouth College | Anti-gp39-antistoffer og anvendelse deraf |
| US6040137A (en) * | 1995-04-27 | 2000-03-21 | Tripep Ab | Antigen/antibody specification exchanger |
| US7807182B2 (en) * | 1996-12-31 | 2010-10-05 | Colorado State University Research Foundation | Early detection of mycobacterial disease using peptides |
| FR2771640B1 (fr) * | 1997-12-03 | 2000-02-11 | Inst Nat Sante Rech Med | Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques |
| US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| BR9909472A (pt) * | 1998-04-07 | 2001-09-11 | Corixa Corp | Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica |
| EP1073667A2 (en) | 1998-04-28 | 2001-02-07 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
| AU4954899A (en) * | 1998-06-26 | 2000-01-17 | Trustees Of Dartmouth College | Methods and compositions for modulating antigen-specific immunological (humoral)responses by targeting such antigen to apcs in conjunction with anti-cd40 ligan d administration |
| US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| WO2001026608A2 (en) | 1999-10-14 | 2001-04-19 | Ledbetter Jeffrey A | Dna vaccines encoding antigen linked to a domain that binds cd40 |
| EP1255560B1 (en) * | 2000-02-02 | 2008-10-29 | UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE | Cd40 ligand adjuvant for respiratory syncytial virus vaccine |
| AU2001259215A1 (en) | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| US7560534B2 (en) * | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| US20040058861A1 (en) * | 2000-09-08 | 2004-03-25 | Pierre Caudrelier | Use of lipopeptides in immunotherapy of HIV+ individuals |
| CA2424296A1 (en) | 2000-10-02 | 2002-04-11 | Chiron Corporation | Human anti-cd40 antibodies |
| PT1391464E (pt) * | 2001-04-27 | 2007-11-15 | Kirin Pharma Kk | Anticorpo monoclonal anti-cd40 |
| CA2492823A1 (en) * | 2001-09-14 | 2003-03-27 | Martin F. Bachmann | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| WO2003029296A1 (en) | 2001-10-02 | 2003-04-10 | Chiron Corporation | Human anti-cd40 antibodies |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| AU2003208415B2 (en) * | 2002-02-14 | 2009-05-28 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| AU2003243651B2 (en) * | 2002-06-17 | 2008-10-16 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Specificity grafting of a murine antibody onto a human framework |
| US8025873B2 (en) | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| CN100381463C (zh) | 2002-09-18 | 2008-04-16 | 中国人民解放军免疫学研究所 | 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途 |
| US20040146948A1 (en) | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| JP2004192125A (ja) | 2002-12-09 | 2004-07-08 | Mitsue-Links Co Ltd | プロジェクトマネジメントシステム及びそれに用いられるデータ構造、並びに、プロジェクトマネジメント方法 |
| GB0228796D0 (en) * | 2002-12-11 | 2003-01-15 | Adjuvantix Ltd | Valency |
| JP2007516157A (ja) * | 2003-02-06 | 2007-06-21 | トリペップ アクチ ボラゲット | グリコシル化された抗原／抗体又はリガンド／受容体特異性交換体 |
| AU2004215489B2 (en) * | 2003-02-25 | 2010-07-15 | Nykode Therapeutics ASA | Modified antibody |
| US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| EP1791866A2 (en) * | 2004-08-11 | 2007-06-06 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
| PL1885399T3 (pl) | 2005-05-26 | 2011-04-29 | Seattle Genetics Inc | Humanizowane przeciwciała anty-CD40 i sposoby ich stosowania |
| JP2007026135A (ja) | 2005-07-19 | 2007-02-01 | Shimizu Corp | プログラムマネジメントチャート作成支援システム |
| CA2620667A1 (en) | 2005-08-30 | 2007-04-12 | Board Of Regents Of The University Of Nebraska | Methods and compositions for vaccination of animals with prrsv antigens with improved immunogenicity |
| ATE469657T1 (de) * | 2005-10-07 | 2010-06-15 | Proyecto Biomedicina Cima Sl | Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c |
| AU2006301846A1 (en) | 2005-10-13 | 2007-04-19 | Akshaya Bio Inc. | Chimeric antigen containing hepatitis C virus polypeptide and FC fragment for eliciting an immune response |
| WO2007051169A2 (en) * | 2005-10-28 | 2007-05-03 | Centocor, Inc. | Use of b cell expansion agents in generating antibodies |
| WO2007103048A2 (en) * | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| CN104357469B (zh) * | 2006-05-03 | 2018-10-26 | 科罗拉多州立大学董事会 | Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其用途 |
| US20080241139A1 (en) * | 2006-10-31 | 2008-10-02 | Regents Of The University Of Colorado | Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity |
| EP2527363A1 (en) * | 2007-02-02 | 2012-11-28 | Baylor Research Institute | Vaccines based on targeting antigen to dcir expressed on antigen-presenting cells |
| TWI422594B (zh) * | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| MX2009008143A (es) * | 2007-02-02 | 2009-10-20 | Baylor Res Inst | Antienos multivariables acomplejados con anticuerpo monoclonal humanizado de apuntamiento. |
| US20090023822A1 (en) * | 2007-07-19 | 2009-01-22 | Tijm Peter J | Method for activating and regenerating catalyst for a fischer-tropsch synthesis reaction |
| EP2058000A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Immunogenic compositions capable of activating T cells |
| TW200936889A (en) | 2008-02-26 | 2009-09-01 | Nidec Corp | Axial flow fan unit |
| JP5233505B2 (ja) | 2008-03-17 | 2013-07-10 | 株式会社リコー | 共同作業支援装置、共同作業支援システム、共同作業支援方法、プログラムおよび記録媒体 |
| AU2010222929B2 (en) * | 2008-07-16 | 2013-07-25 | Baylor Research Institute | Antigen presenting cell targeted anti-viral vaccines |
| NZ596171A (en) | 2008-07-16 | 2012-05-25 | Baylor Res Inst | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| AU2010222942B2 (en) | 2009-03-10 | 2013-01-10 | Baylor Research Institute | Anti-CD40 antibodies and uses thereof |
| CA2754743C (en) * | 2009-03-10 | 2020-08-25 | Baylor Research Institute | Antigen presenting cell targeted anti-viral vaccines |
| AU2010291939B2 (en) | 2009-09-14 | 2012-11-15 | Baylor Research Institute | Vaccines directed to Langerhans cells |
| US20110274653A1 (en) | 2010-05-07 | 2011-11-10 | Baylor Research Institute | Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells |
-
2010
- 2010-03-04 AU AU2010222929A patent/AU2010222929B2/en active Active
- 2010-03-04 ES ES16189342T patent/ES2911752T3/es active Active
- 2010-03-04 US US12/717,804 patent/US8518410B2/en active Active
- 2010-03-04 MX MX2011009439A patent/MX2011009439A/es active IP Right Grant
- 2010-03-04 BR BRPI1009194A patent/BRPI1009194A2/pt not_active IP Right Cessation
- 2010-03-04 CN CN201510812474.0A patent/CN105837691B/zh active Active
- 2010-03-04 CN CN2010800205317A patent/CN102770457A/zh active Pending
- 2010-03-04 DK DK16189342.5T patent/DK3138854T3/da active
- 2010-03-04 MX MX2011009441A patent/MX337397B/es active IP Right Grant
- 2010-03-04 EP EP17153786.3A patent/EP3219732A1/en not_active Ceased
- 2010-03-04 ES ES10751210.5T patent/ES2635080T3/es active Active
- 2010-03-04 US US12/717,789 patent/US8961991B2/en active Active
- 2010-03-04 AU AU2010222928A patent/AU2010222928B2/en active Active
- 2010-03-04 CN CN201610087314.9A patent/CN105884903B/zh active Active
- 2010-03-04 CN CN201810270829.1A patent/CN108373509A/zh active Pending
- 2010-03-04 CN CN201080020430XA patent/CN102741295A/zh active Pending
- 2010-03-04 BR BRPI1009458A patent/BRPI1009458A2/pt not_active IP Right Cessation
- 2010-03-05 DK DK16159238.1T patent/DK3091034T3/da active
- 2010-03-05 PT PT161592381T patent/PT3091034T/pt unknown
- 2010-03-05 ES ES16159238T patent/ES2807232T3/es active Active
- 2010-03-05 EP EP16159238.1A patent/EP3091034B1/en active Active
- 2010-03-10 TW TW099106976A patent/TWI542358B/zh not_active IP Right Cessation
- 2010-03-10 TW TW099106978A patent/TWI505835B/zh not_active IP Right Cessation
- 2010-03-10 AR ARP100100737A patent/AR078693A1/es not_active Application Discontinuation
- 2010-03-10 AR ARP100100735A patent/AR076107A1/es active IP Right Grant
-
2013
- 2013-08-26 US US13/975,786 patent/US9416186B2/en active Active
-
2015
- 2015-01-30 US US14/610,456 patent/US20150299329A1/en not_active Abandoned
-
2017
- 2017-10-18 US US15/787,425 patent/US10988544B2/en active Active
-
2021
- 2021-03-25 US US17/301,118 patent/US20210221904A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2635080T3 (es) | Vacunas contra el cáncer dirigidas a células presentadoras de antígenos | |
| US11806390B2 (en) | Fusion proteins comprising an anti-CD40 antibody and cancer antigens | |
| AU2012261572B2 (en) | Antigen Presenting Cell Targeted Vaccines |